Muscle Preserve — Evidence Dossier
LipoCentric Nutra · Scientific Reference
Muscle Preserve™ Evidence Dossier
Every load-bearing claim in the Muscle Preserve™ formulation, with its mechanism, the key human evidence, an evidence tier, and an honest note on how far the claim can be pushed before it outruns the data.
Version 1.0 · Formulation basis: 3.0 g L-leucine · ~9.3 g complete EAAs · myHMB® 3.0 g/day · taurine 1.0 g · sunflower phospholipid 500 mg
Purpose & how to read this. This document exists so that any claim made on the pack, the science page, the keynote, or in a physician conversation can be traced to its evidence and defended — or, where the evidence is thinner than the marketing, softened before it is challenged. Each claim carries an evidence tier and a "limits of the claim" box. The limits box is the most important part: it is written to be read before a regulator, a skeptical endocrinologist, or a competitor's medical-affairs team reads the claim. Citations are for verification; final citation formatting and any published or promotional use should be confirmed by your regulatory/scientific reviewer. Nothing here is a medical or therapeutic claim about the finished product.
Evidence tiers:
STRONG — RCT / consistent human evidence
MODERATE — supportive but mixed or limited
EMERGING — mechanistic / early
CONTEXT — background epidemiology, not a product claim
At a glance
| # | Claim | Ingredient / basis | Tier |
|---|---|---|---|
| 1 | A ~3 g per-serving leucine dose reaches the researched per-meal anabolic signal | L-leucine 3.0 g | MODERATE |
| 2 | All nine essential amino acids are required to complete muscle protein synthesis | Complete EAAs ~9.3 g | STRONG |
| 3 | Free-form EAAs need no digestion and are absorbed rapidly and near-completely | Free-form EAA matrix | STRONG |
| 4 | MPS has a per-meal ceiling (~20 g protein); excess yields diminishing muscle-specific return | Formulation rationale | STRONG |
| 5 | HMB at 3 g/day helps reduce muscle protein breakdown / preserves lean mass during stress | myHMB® 3.0 g/day | MODERATE |
| 6 | Taurine supports cellular hydration and normal muscle function | Taurine 1.0 g | EMERGING |
| 7 | Sunflower phospholipid improves dispersion/mouthfeel; keeps product dairy- & soy-allergen-free | Sunflower lecithin 500 mg | MODERATE |
| 8 | Muscle declines with age; reduced intake / GLP-1 therapy accelerates lean-mass loss | Category context | CONTEXT |
Full substantiation
MODERATE
CLAIM 1 · TRIGGER
A 3.0 g per-serving leucine dose reaches the researched per-meal anabolic signal, which rises with age.
Mechanism
Leucine activates the mTORC1 pathway that initiates muscle protein synthesis (MPS). The amplitude and speed of the rise in circulating leucine are considered primary determinants of the response. Isoleucine and valine do not share this direct triggering role, which is why the formula is deliberately leucine-forward.
Evidence
A per-meal leucine reference of ~2.5–3 g to maximally stimulate MPS is widely cited, with older adults generally requiring the upper end (or more) due to anabolic resistance — a documented "rightward shift" in the dose–response relationship. The 3.0 g dose is chosen against this upper reference.
Key sources
Wilkinson DJ et al. Association of postprandial post-exercise MPS rates with dietary leucine: a systematic review. Physiol Rep 2023;11:e15775 (PMC10400406). · Breen & Phillips (leucine-trigger hypothesis, 2011). · Katsanos CS et al. Am J Physiol Endocrinol Metab 2006.
Limits of the claim. The 2.5–3 g figure is a widely-used practical reference, not a hard-proven universal cut-off. The 2023 Wilkinson systematic review found leucine dose predicted MPS in older adults but explicitly identified no discrete threshold and no single plasma-leucine variable that reliably predicted the response. Claim as "a clinically relevant / researched leucine signal," never "the proven threshold" or "clinically proven to build muscle." State as formulation rationale, not finished-product efficacy.
STRONG
CLAIM 2 · BUILD
All nine essential amino acids are required to complete new muscle protein; the formula supplies the complete set.
Mechanism
Muscle protein is built from all nine EAAs (those the body cannot synthesise). A leucine trigger without the full substrate cannot complete synthesis — a signal without materials builds nothing. The EAAs are the fraction of dietary protein primarily responsible for the anabolic response.
Evidence
Volpi et al. showed essential amino acids are primarily responsible for the amino-acid stimulation of muscle protein anabolism in healthy elderly adults; non-essential amino acids were not required for the response.
Key sources
Volpi E, Kobayashi H, Sheffield-Moore M, Mittendorfer B, Wolfe RR. Am J Clin Nutr 2003;78(2):250–258. · Church DD, Ferrando AA, Wolfe RR et al. Front Nutr 2024;11:1360312 (PMC10957733).
Limits of the claim. "Required to complete muscle protein synthesis" is defensible physiology. Do not extend to a finished-product efficacy claim ("builds muscle") without SKU-specific evidence you do not yet have. The claim is about the necessity of complete EAAs, not a measured outcome from this product.
STRONG
CLAIM 3 · DELIVERY
Free-form EAAs need no digestion and are absorbed rapidly and near-completely — a faster, more direct signal than the same amino acids bound in whole protein.
Mechanism
Free amino acids bypass the proteolysis intact protein requires before its amino acids are released, producing a more rapid rise in circulating amino acids, including leucine. Because every gram is essential, the dose is directed at the signal rather than diluted through a larger protein load.
Evidence
Low-dose, high-leucine EAA compositions stimulate MPS efficiently; free-form EAAs appear in the circulation faster than the amino acids from intact protein.
Key sources
Church DD, Ferrando AA, Wolfe RR. Front Nutr 2024;11:1360312. · Volpi E et al. Am J Clin Nutr 2003 (EAA kinetics).
Limits of the claim. Do not claim "more bioavailable than whey" or imply whey is poorly absorbed — whey is highly bioavailable (~90%+) and the anabolic benchmark. The defensible claim is speed and per-gram efficiency, not superior absorption. Avoid "100% absorbed" — a large free-amino-acid bolus can show some intestinal competition; "rapidly and near-completely absorbed" is the safe ceiling.
STRONG
CLAIM 4 · CEILING
Muscle protein synthesis has a per-meal ceiling (~20 g high-quality protein); protein beyond it yields diminishing muscle-specific return.
Mechanism
MPS rises with protein dose and plateaus; beyond the ceiling the surplus is increasingly directed toward oxidation and other functions rather than additional muscle. Amino acids are not stored for later use.
Evidence
Moore et al.: MPS maximised at ~20 g protein post-exercise in young men, little further gain at 40 g. Witard et al.: plateau confirmed with whey (~20 g maximal; excess oxidised). Schoenfeld & Aragon: review of the per-meal ceiling and daily-distribution implications.
Key sources
Moore DR et al. Am J Clin Nutr 2009;89(1):161–168. · Witard OC et al. Am J Clin Nutr 2014;99(1):86–95. · Schoenfeld BJ, Aragon AA. J Int Soc Sports Nutr 2018;15:10.
Limits of the claim. Say "diminishing return for muscle specifically," never "excess protein is wasted" — the body uses surplus protein for energy and other functions, and newer work (Trommelen 2023) shows even very large protein doses contribute to MPS over longer windows. The ceiling is a per-meal, muscle-specific point. The higher end (~40 g/meal) applies to older adults and critical illness.
MODERATE
CLAIM 5 · PRESERVE (HMB)
myHMB® at 3 g/day helps reduce muscle protein breakdown and preserve lean mass during physiological stress such as calorie restriction, inactivity, and aging.
Mechanism
HMB (β-hydroxy-β-methylbutyrate), a leucine metabolite, is associated primarily with reduced muscle protein breakdown (with some support of synthesis and cell-membrane integrity) under catabolic conditions. Only ~5% of dietary leucine converts to HMB, so the studied 3 g/day cannot be reached from leucine or whey alone.
Evidence
Landmark RCT (Deutz 2013): 24 healthy older adults (mean age ~67), 10 days complete bed rest, HMB 3 g/day (1.5 g Ca-HMB × 2, TSI) started 5 days prior. Placebo group lost ~2 kg lean body mass; HMB group preserved lean mass (significant between-group difference). Systematic reviews/meta-analyses in older adults support HMB for fat-free-mass preservation; additional supportive data in clinical/wasting settings.
Key sources
Deutz NEP et al. Clin Nutr 2013;32(5):704–712 (PMID 23514626; NCT00945581). · Older-adult HMB meta-analyses (fat-free mass). · Cruz-Jentoft AJ. Curr Protein Pept Sci 2018;19(7):668–672.
Limits of the claim. Strongest data is muscle-mass preservation in older / disuse / clinical / calorie-restricted settings. Evidence for strength and physical-function outcomes is genuinely mixed — e.g. Din et al. 2019 (HMB free-acid + resistance training, older men) found no added benefit over placebo. State HMB as "helps reduce muscle protein breakdown / supports lean-mass preservation during physiological stress," attributed to studied populations — not "builds muscle," "increases strength," or anything GLP-1-specific (no GLP-1 HMB trials exist). Note Deutz trial's Abbott/TSI affiliations for disclosure.
EMERGING
CLAIM 6 · SUPPORT (Taurine)
Taurine supports cellular hydration and normal muscle function.
Mechanism
Conditionally essential amino acid involved in cell-volume/osmoregulation, calcium handling, and antioxidant defence in skeletal muscle. Included as a functional support ingredient, not a headline anti-catabolic agent.
Evidence
Mechanistic and exercise-physiology literature supports roles in cellular hydration and muscle function; direct human muscle-preservation outcome data is limited relative to HMB.
Limits of the claim. Keep framed as "supports cellular hydration and normal muscle function" — a permitted functional-support statement. Do not attribute muscle preservation or performance outcomes to taurine specifically; present as adjunctive.
MODERATE
CLAIM 7 · FORMULATION (Phospholipid)
Non-GMO sunflower lecithin improves dispersion, mixability and mouthfeel, and keeps the formula free of dairy and soy allergens.
Role
Included solely as a formulation/sensory aid (dispersion, wettability, reduced foaming, mouthfeel). Being sunflower-derived, it avoids soy and dairy allergens, consistent with the dairy-free positioning.
Evidence
Lecithin's emulsification/dispersion function in powder formulation is well established; allergen-free status follows from the sunflower source.
Limits of the claim. A formulation/sensory claim only. Do not present the phospholipid as an absorption, delivery, or bioavailability enhancer for the amino acids — they are already highly bioavailable in free form. Confirm the specific sensory benefit with supplier documentation before stating it on-pack.
CONTEXT
CLAIM 8 · CATEGORY CONTEXT
Muscle declines with age, and reduced intake — including GLP-1/GIP therapy — accelerates lean-mass loss.
Basis
Skeletal muscle declines ~8% per decade after age 40, accelerating to ~15% per decade after 70 (sarcopenia). On GLP-1 / dual GLP-1–GIP therapies, published analyses attribute roughly 25–40% of total weight lost to lean body mass. Indian populations may be at elevated risk (lower baseline protein intake and muscle mass). Clinical guidance recommends ~1.2–1.5 g/kg/day protein during weight-loss therapy.
Key sources
Age decline: skeletal-muscle aging literature (Grimby & Saltin; Wu H et al. Arch Gerontol Geriatr 2015). · GLP-1 lean-mass: Neeland IJ et al. Diabetes Obes Metab 2024;26(Suppl 4):16–27. · Protein guidance: 1.2–1.5 g/kg/day expert consensus.
Limits of the claim. Background context that establishes the problem — not a claim that the product treats, prevents, or reverses sarcopenia or drug-related muscle loss. Keep GLP-1 references to the physiological circumstance (reduced intake, appetite suppression), never implying the product is a therapy for, or interacts with, any medication. Pin the ~8%/decade figure to a specific primary source before formal publication.
Standing claim-language rules
Always safe framing
"Supports lean muscle as part of an adequate diet." · "A clinically relevant / researched leucine signal." · "HMB helps reduce muscle protein breakdown during physiological stress such as calorie restriction, inactivity and aging." · "Free-form amino acids are absorbed rapidly and near-completely, without the digestion whole protein requires." · "Designed for a reduced appetite / compact serving."
Never claim
Builds/increases muscle or strength (finished-product outcome, unproven for this SKU) · "clinically proven" anything · "more bioavailable than whey" / whey poorly absorbed · HMB improves strength/function (mixed evidence) · any GLP-1 drug-specific efficacy or interaction · treats/prevents/reverses sarcopenia, obesity, or diabetes · "excess protein is wasted" · phospholipid as an absorption enhancer.
Reviewer notes. (1) Several figures are cited at review level and should be pinned to a definitive primary source before published/promotional use: the ~8%/decade aging-decline figure, the leucine-threshold reference range, and general HMB fat-free-mass meta-analytic estimates. (2) The Deutz 2013 HMB trial has Abbott/TSI author affiliations — disclose when cited clinically. (3) The finished product has no SKU-specific clinical trial; all efficacy language must stay at the ingredient-rationale level, not the product-outcome level, until such data exists. (4) Living document — update tiers and citations as new evidence (or the company's own studies) appears. © LipoCentric Nutra. This document is the property of LipoCentric Nutra. Reproduction, redistribution or reuse of its content, in whole or in part, is not permitted without written permission.